Intellia Therapeutics (NASDAQ:NTLA) Earns "Neutral" Rating from Wedbush

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report)'s stock had its "neutral" rating reiterated by stock analysts at Wedbush in a research note issued to investors on Monday,RTT News reports. They presently have a $7.00 target price on the stock. Wedbush's price target indicates a potential downside of 27.08% from the company's current price.

NTLA has been the topic of several other reports. Wells Fargo & Company lowered their price target on shares of Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Citigroup lowered their target price on Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating on the stock in a research note on Friday, May 9th. Barclays cut their price target on Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. Guggenheim lowered their price target on Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating for the company in a research note on Monday, May 12th. Finally, The Goldman Sachs Group reaffirmed a "sell" rating and set a $9.00 price objective on shares of Intellia Therapeutics in a research report on Friday, February 28th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Intellia Therapeutics has an average rating of "Moderate Buy" and an average target price of $34.95.

Intellia Therapeutics Stock Up 0.2%

NASDAQ:NTLA traded up $0.02 during trading hours on Monday, hitting $9.60. 5,758,175 shares of the company's stock traded hands, compared to its average volume of 2,883,590. The stock's fifty day moving average price is $8.24 and its two-hundred day moving average price is $9.74. Intellia Therapeutics has a twelve month low of $5.90 and a twelve month high of $28.18.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share for the quarter, beating analysts' consensus estimates of ($1.26) by $0.16. Intellia Therapeutics had a negative return on equity of 56.06% and a negative net margin of 1,154.10%. The company had revenue of $16.63 million for the quarter, compared to the consensus estimate of $11.39 million. During the same quarter in the prior year, the company earned ($1.12) EPS. The firm's quarterly revenue was down 42.6% on a year-over-year basis. On average, sell-side analysts forecast that Intellia Therapeutics will post -5.07 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Intellia Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System raised its stake in Intellia Therapeutics by 4.1% during the 4th quarter. California State Teachers Retirement System now owns 90,638 shares of the company's stock valued at $1,057,000 after purchasing an additional 3,596 shares during the last quarter. ARK Investment Management LLC increased its holdings in shares of Intellia Therapeutics by 2.3% during the 4th quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company's stock worth $146,174,000 after purchasing an additional 280,946 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Intellia Therapeutics during the fourth quarter valued at about $4,793,000. Baker BROS. Advisors LP bought a new stake in shares of Intellia Therapeutics in the fourth quarter valued at about $7,510,000. Finally, XTX Topco Ltd grew its position in Intellia Therapeutics by 194.6% during the fourth quarter. XTX Topco Ltd now owns 43,908 shares of the company's stock worth $512,000 after buying an additional 29,006 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company's stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.